| Автор | Lippman, Scott M. |
| Автор | Kavanagh, John J. |
| Автор | Paredes-Espinoza, Mario |
| Автор | Delgadillo-Madrueño, Fernando |
| Автор | Paredes-Casillas, Patricia |
| Автор | Hong, Waun Ki |
| Автор | Holderner, Eduardo |
| Автор | Krakoff, Irwin H. |
| Дата выпуска | 1992 |
| dc.description | Background: Chemotherapeutic study of cervical squamous cell carcinoma has shown some positive results. Com–plete plus partial (overall) response rates of 15% -35% (complete response rate, < 5% ) were achieved with the use of a small number of cytotoxic single agents in patients with advanced disease. In addition, overall response rates of 60% -70% (complete response rates, 10% -20% ) were achieved with cisplatin-based, multiagent regimens in patients with primary, locally ad–vanced disease. However, the lack of clear evidence that existing chemo–therapy can achieve a survival benefit, coupled with the worldwide annual deaths of hundreds of thousands of women from cervical cancer, indicates the urgent need for effective systemic therapy for this disease. Purpose: In view of the preclinical and clinical evidence that supports testing of the novel combination of 13-cis-retinoic acid (13-cRA) plus interferon-α (IFN-α) in cervical squamous cell carcinoma, we conducted a phase II study of this regimen in locally advanced disease. Methods: Twenty-six patients with un–treated, locally advanced squamous cell carcinoma of the cervix were treated daily for at least 2 months with oral 13-cRA (1 mg/ kg) and subcutaneous recombinant human IFN α -2a (6 mil–lion units). In 21 patients (81% ), the disease was stage II or higher. Results: Thirteen patients (50% ) experienced major responses (tumor regression ≥ 50% ) in association with resolution of symptoms; one achieved complete response, and 12 experienced partial response. Seven with partial response are improving further, four are being maintained in partial response, and one responder has relapsed during therapy. The response rate is 58% (11 of 19) in patients with stage IIB or higher disease and 66% (10 of 15) in patients with bulky disease (at least one dimension ≥ 10 cm). Of the 13 non-responders, nine have stable disease and four have had disease progression during therapy. Toxicity was minimal. Conclusion: These preliminary results indicate that systemic 13-cRA plus IFN α -2a is a highly active, well-tolerated therapy for locally advanced cervical cancer. [J Natl Cancer Inst 84:241– 245, 1992] |
| Формат | application.pdf |
| Издатель | Oxford University Press |
| Копирайт | © Oxford University Press |
| Тема | Reports |
| Название | 13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix |
| Тип | other |
| Electronic ISSN | 1460-2105 |
| Print ISSN | 0027-8874 |
| Журнал | JNCI: Journal of the National Cancer Institute |
| Том | 84 |
| Первая страница | 241 |
| Последняя страница | 245 |
| Аффилиация | Lippman Scott M.; Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center |
| Аффилиация | Kavanagh John J.; Department of Medical Oncology and Department of Gynecology, The University of Texas M. D. Anderson Cancer Center |
| Аффилиация | Paredes-Espinoza Mario; Department of Medicine, Hospital Civil de Guadalajara, and Instituto Jalisciense de Cancerologia |
| Аффилиация | Delgadillo-Madrueño Fernando; Department of Medicine, Hospital Civil de Guadalajara, and Instituto Jalisciense de Cancerologia |
| Аффилиация | Paredes-Casillas Patricia; Department of Medicine, Hospital Civil de Guadalajara, and Instituto Jalisciense de Cancerologia |
| Аффилиация | Hong Waun Ki; Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center |
| Аффилиация | Holderner Eduardo; |
| Аффилиация | Krakoff Irwin H.; Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center |
| Выпуск | 4 |
